{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:48:32Z","timestamp":1790192912835,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100012304","name":"School of Medicine, Johns Hopkins University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012304","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014804","name":"Neurofibromatosis Therapeutic Acceleration Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007880","name":"Johns Hopkins University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007880","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.jid.2023.01.041","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T01:36:29Z","timestamp":1686188189000},"page":"1388-1396","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Target Product Profile for Cutaneous Neurofibromas: Clinical Trials to Prevent, Arrest, or Regress Cutaneous Neurofibromas"],"prefix":"10.1016","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0494-2946","authenticated-orcid":false,"given":"Ina","family":"Ly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0260-7047","authenticated-orcid":false,"given":"Carlos G.","family":"Romo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7318-0055","authenticated-orcid":false,"given":"Sally","family":"Gottesman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5988-2197","authenticated-orcid":false,"given":"Kristen M.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6286-2069","authenticated-orcid":false,"given":"Deanna","family":"Kornacki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4845-9940","authenticated-orcid":false,"given":"Zachary","family":"York","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3911-8316","authenticated-orcid":false,"given":"Sang Y.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6551-8631","authenticated-orcid":false,"given":"Steven D.","family":"Rhodes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7874-5585","authenticated-orcid":false,"given":"Verena","family":"Staedtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9003-6730","authenticated-orcid":false,"given":"Matthew R.","family":"Steensma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1049-0993","authenticated-orcid":false,"given":"Jaishri O.","family":"Blakeley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8194-457X","authenticated-orcid":false,"given":"Pierre","family":"Wolkenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2023.01.041_bib1","unstructured":"Anderson RR, Funk M, Sakamoto F, Plotkin SR, Garibyan L, Vogel K, et\u00a0al. Non-invasive treatment of cutaneous neurofibromas (cNF): preliminary results of a prospective, direct comparison of four methods. Paper presented at: 2022 Neurofibromatosis Conference. 2022; Philadelphia; Pennsylvania."},{"key":"10.1016\/j.jid.2023.01.041_bib2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13023-020-1310-3","article-title":"Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966","volume":"15","author":"Bergqvist","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jid.2023.01.041_bib3","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/00000637-198204000-00002","article-title":"Neurofibromatosis-distribution of lesions and surgical treatment","volume":"8","author":"Bromley","year":"1982","journal-title":"Ann Plast Surg"},{"key":"10.1016\/j.jid.2023.01.041_bib4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13023-018-0772-z","article-title":"Cutaneous neurofibromas in Neurofibromatosis type I: a quantitative natural history study","volume":"13","author":"Cannon","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jid.2023.01.041_bib5","article-title":"Robust surgical approach for cutaneous neurofibroma in neurofibromatosis type 1","volume":"5","author":"Chamseddin","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.jid.2023.01.041_bib6","first-page":"i107","article-title":"Management of cutaneous neurofibroma: current therapy and future directions","volume":"2","author":"Chamseddin","year":"2020","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.jid.2023.01.041_bib7","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nrc1071","article-title":"Photodynamic therapy for cancer","volume":"3","author":"Dolmans","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jid.2023.01.041_bib8","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1159\/000327379","article-title":"Evolving pattern with age of cutaneous signs in neurofibromatosis type 1: a cross-sectional study of 728 patients","volume":"222","author":"Duong","year":"2011","journal-title":"Dermatology"},{"key":"10.1016\/j.jid.2023.01.041_bib9","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/1346-8138.14025","article-title":"Natural course and characteristics of cutaneous neurofibromas in neurofibromatosis 1","volume":"45","author":"Ehara","year":"2018","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jid.2023.01.041_bib10","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10103-007-0485-3","article-title":"Non-excision treatment of multiple cutaneous neurofibromas by laser photocoagulation","volume":"23","author":"Elwakil","year":"2008","journal-title":"Lasers Med Sci"},{"key":"10.1016\/j.jid.2023.01.041_bib15","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1111\/jdv.18140","article-title":"Quality of life in neurofibromatosis 1: development and validation of a tool dedicated to cutaneous neurofibromas in adults","volume":"36","author":"Fertitta","year":"2022","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2023.01.041_bib16","doi-asserted-by":"crossref","first-page":"781","DOI":"10.5114\/ada.2020.100488","article-title":"Clinical picture and treatment of cutaneous lesions in patients with neurofibromatosis type 1","volume":"37","author":"Fija\u0142kowska","year":"2020","journal-title":"Postepy Dermatol Alergol"},{"key":"10.1016\/j.jid.2023.01.041_bib17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/lsm.23497","article-title":"Efficacy and safety of laser-assisted combination chemotherapy: a follow-up study of treatment with 5-fluorouracil and cisplatin for basal cell carcinoma","volume":"54","author":"Fredman","year":"2022","journal-title":"Lasers Surg Med"},{"key":"10.1016\/j.jid.2023.01.041_bib18","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2023.01.041_bib19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13072-020-00380-6","article-title":"Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK\/p38 signaling","volume":"14","author":"Grit","year":"2021","journal-title":"Epigenetics Chromatin"},{"key":"10.1016\/j.jid.2023.01.041_bib20","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in children with inoperable plexiform neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2023.01.041_bib21","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s13023-019-1265-4","article-title":"Cutaneous neurofibromas: patients' medical burden, current management and therapeutic expectations: results from an online\u00a0European patient community survey","volume":"14","author":"Guiraud","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jid.2023.01.041_bib22","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nbt.2786","article-title":"Clinical development success rates for investigational drugs","volume":"32","author":"Hay","year":"2014","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jid.2023.01.041_bib23","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1080\/10717544.2021.1933649","article-title":"Bleomycin administered by laser-assisted drug delivery or intradermal needle-injection results in distinct biodistribution patterns in skin: in\u00a0vivo investigations with mass spectrometry imaging","volume":"28","author":"Hendel","year":"2021","journal-title":"Drug Deliv"},{"key":"10.1016\/j.jid.2023.01.041_bib24","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1093\/brain\/111.6.1355","article-title":"Von Recklinghausen neurofibromatosis: a clinical and population study in south-east Wales","volume":"111","author":"Huson","year":"1988","journal-title":"Brain"},{"key":"10.1016\/j.jid.2023.01.041_bib25","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/jps.22762","article-title":"Skin microdialysis-based estimation of systemic bioavailability fraction","volume":"101","author":"Juluru","year":"2012","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.jid.2023.01.041_bib26","article-title":"27.12 MHz radiofrequency ablation for benign cutaneous lesions","volume":"2016","author":"Kim","year":"2016","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.jid.2023.01.041_bib27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.5999\/aps.2013.40.1.57","article-title":"Radiofrequency ablation and excision of multiple cutaneous lesions in neurofibromatosis type 1","volume":"40","author":"Kim","year":"2013","journal-title":"Arch Plast Surg"},{"key":"10.1016\/j.jid.2023.01.041_bib28","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2165\/11634580-000000000-00000","article-title":"Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin","volume":"12","author":"Koenig","year":"2012","journal-title":"Drugs R D"},{"key":"10.1016\/j.jid.2023.01.041_bib49","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jid.2023.03.1681","article-title":"Current and emerging imaging techniques for neurofibromatosis type 1\u2013associated cutaneous neurofibromas","volume":"143","author":"Li","year":"2023","journal-title":"J Investig Dermatol"},{"key":"10.1016\/j.jid.2023.01.041_bib29","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.bjps.2007.03.035","article-title":"Electrosurgical excision technique for the treatment of multiple cutaneous lesions in neurofibromatosis type I","volume":"61","author":"Levine","year":"2008","journal-title":"J\u00a0Plast Reconstr Aesthet Surg"},{"key":"10.1016\/j.jid.2023.01.041_bib30","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.bjps.2016.03.024","article-title":"The use of electrodessication in the treatment of cutaneous neurofibromatosis: A retrospective patient satisfaction outcome assessment","volume":"69","author":"Lutterodt","year":"2016","journal-title":"J\u00a0Plast Reconstr Aesthet Surg"},{"key":"10.1016\/j.jid.2023.01.041_bib31","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000368078","article-title":"Treatment of neurofibromas with a carbon dioxide laser: a retrospective cross-sectional study of 106 patients","volume":"230","author":"M\u00e9ni","year":"2015","journal-title":"Dermatology"},{"key":"10.1016\/j.jid.2023.01.041_bib32","doi-asserted-by":"crossref","DOI":"10.1172\/JCI139807","article-title":"Humanized neurofibroma model from induced pluripotent stem cells delineates tumor pathogenesis and developmental origins","volume":"131","author":"Mo","year":"2021","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jid.2023.01.041_bib33","unstructured":"National Archives. Pathological complete response in neoadjuvant treatment of high-risk early-stage breast cancer: use as an endpoint to support accelerated approval; guidance for industry; availability, https:\/\/www.federalregister.gov\/documents\/2014\/10\/07\/2014-23845\/pathological-complete-response-in-neoadjuvant-treatment-of-high-risk-early-stage-breast-cancer-use; 2014 (accessed September 5, 2022)."},{"key":"10.1016\/j.jid.2023.01.041_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2021.e06518","article-title":"Clinical assessment of the use of topical liquid diclofenac following laser microporation of cutaneous neurofibromas in individuals with neurofibromatosis type 1","volume":"7","author":"Oliveira","year":"2021","journal-title":"Heliyon"},{"key":"10.1016\/j.jid.2023.01.041_bib35","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1111\/j.1524-4725.2010.01666.x","article-title":"The megasession technique for excision of multiple neurofibromas","volume":"36","author":"Onesti","year":"2010","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jid.2023.01.041_bib36","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1212\/WNL.0000000000005792","article-title":"Cutaneous neurofibromas: current clinical and pathologic issues","volume":"91","author":"Ortonne","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.jid.2023.01.041_bib37","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/ajmg.a.31422","article-title":"Impact of neurofibromatosis 1 on Quality of Life: a cross-sectional study of 176 American cases","volume":"140","author":"Page","year":"2006","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.jid.2023.01.041_bib38","first-page":"368","article-title":"[Plastic surgery in benign cutaneous manifestations of von Recklinghausen's disease]","volume":"116","author":"Pailheret","year":"1990","journal-title":"Chirurgie"},{"key":"10.1016\/j.jid.2023.01.041_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmg.2021.104386","article-title":"Treatment of cutaneous neurofibromas with carbon dioxide laser: technique and patient experience","volume":"65","author":"Peltonen","year":"2022","journal-title":"Eur J Med Genet"},{"key":"10.1016\/j.jid.2023.01.041_bib40","first-page":"411","article-title":"Photodynamic therapy for benign cutaneous neurofibromas using aminolevulinic acid topical application and 633 nm red light illumination","volume":"39","author":"Quirk","year":"2021","journal-title":"Photobiomodul Photomed Laser Surg"},{"key":"10.1016\/j.jid.2023.01.041_bib41","unstructured":"Sarin KY, Berger B, O\u2019Mara C, Webster G, Shahryani J, Kincaid J, et\u00a0al. Phase IIa trial of topical MEK inhibitor, NFX-179, in neurofibromatosis type 1 patients with cutaneous neurofibromas. Paper presented at: Neurofibromatosis Conference. 2021; Virtual."},{"key":"10.1016\/j.jid.2023.01.041_bib42","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0928-0987(00)00155-X","article-title":"Microdialysis for the evaluation of penetration through the human skin barrier - a promising tool for future research?","volume":"12","author":"Schnetz","year":"2001","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.jid.2023.01.041_bib43","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40268-018-0248-6","article-title":"Treatment of disfiguring cutaneous lesions in neurofibromatosis-1 with everolimus: a phase II, open-label, single-arm trial","volume":"18","author":"Slopis","year":"2018","journal-title":"Drugs R D"},{"key":"10.1016\/j.jid.2023.01.041_bib50","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.jid.2023.01.042","article-title":"Existing and developing preclinical models for neurofibromatosis type 1\u2013related cutaneous neurofibromas","volume":"143","author":"Staedtke","year":"2023","journal-title":"J Investig Dermatol"},{"key":"10.1016\/j.jid.2023.01.041_bib44","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1212\/WNL.0000000000012428","article-title":"Validating techniques for measurement of cutaneous neurofibromas: recommendations for clinical trials","volume":"97","author":"Thalheimer","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.jid.2023.01.041_bib45","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1212\/WNL.0000000000012426","article-title":"Status and recommendations for incorporating biomarkers for cutaneous neurofibromas into clinical research","volume":"97","author":"Wallis","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.jid.2023.01.041_bib46","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1001\/archderm.139.1.103","article-title":"Visibility of neurofibromatosis 1 and psychiatric morbidity","volume":"139","author":"Wolkenstein","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jid.2023.01.041_bib47","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1212\/WNL.0000000000012421","article-title":"Current recommendations for patient-reported outcome measures assessing domains of quality of life in neurofibromatosis clinical trials","volume":"97","author":"Wolters","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.jid.2023.01.041_bib48","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1346-8138.2007.00258.x","article-title":"Treatment of pigmented lesions of neurofibromatosis 1 with intense pulsed-radio frequency in combination with topical application of vitamin D3 ointment","volume":"34","author":"Yoshida","year":"2007","journal-title":"J\u00a0Dermatol"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X23019619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X23019619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T17:34:16Z","timestamp":1758303256000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X23019619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0022202X23019619"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2023.01.041","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Target Product Profile for Cutaneous Neurofibromas: Clinical Trials to Prevent, Arrest, or Regress Cutaneous Neurofibromas","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2023.01.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}